Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 2;11(7):2003.
doi: 10.3390/jcm11072003.

Embolic Protection with the TriGuard 3 System in Nonagenarian Patients Undergoing Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis

Alexander Lind  1 , Rolf Alexander Jánosi  1 , Matthias Totzeck  1 , Arjang Ruhparwar  2 , Tienush Rassaf  1 , Fadi Al-Rashid  1
Affiliations

Embolic Protection with the TriGuard 3 System in Nonagenarian Patients Undergoing Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis

Alexander Lind et al. J Clin Med. .

Abstract

Background: Transcatheter aortic valve replacement (TAVR) improves the survival and life quality of nonagenarian patients with aortic stenosis. Stroke remains one of the most worrisome complications following TAVR. Cerebral embolic protection devices (CEPDs) may reduce neurological complications after TAVR. This study evaluated the safety and efficacy of CEPDs during TAVR in nonagenarian patients.

Methods: Between January 2018 and October 2021, 869 patients underwent transfemoral TAVR (TF-TAVR) at our center. Of these, 51 (5.9%) patients were older than ninety years. In 33 consecutive nonagenarian patients, TF-TAVR was implanted without CEPDs using balloon-expandable valves (BEVs) and self-expandable valves (SEVs). Eighteen consecutive nonagenarians underwent TF-TAVR using a CEPD (CP group). Follow up period was in-hospital or 30 days after the procedure, respectively.

Results: Minor access site complications occurred in two patients (3.9%) and were not CEPD-associated. Postinterventional delirium occurred in nine patients (17.6%). Periprocedural minor non-disabling stroke and delirium occurred in ten patients (19.6%). Periprocedural major fatal stroke occurred in two patients in the BEV group (3.9%). Two patients in the BEV group died due to postinterventional pneumonia with sepsis. The mortality rate was 7.8%. The results did not differ between the groups.

Conclusions: Age alone is no longer a contraindication for TAVR. CEPD using the Triguard 3 system in nonagenarian TAVR patients was feasible and safe and did not increase access site complications.

Keywords: TAVR; embolic protection; interventional devices; nonagenarians; percutaneous valve therapy; stroke.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Nkomo V.T., Gardin J.M., Skelton T.N., Gottdiener J.S., Scott C.G., Enriquez-Sarano M. Burden of valvular heart diseases: A population-based study. Lancet. 2006;368:1005–1011. doi: 10.1016/S0140-6736(06)69208-8. - DOI - PubMed
    1. Smith C.R., Leon M.B., Mack M.J., Miller D.C., Moses J.W., Svensson L.G., Tuzcu E.M., Webb J.G., Fontana G.P., Makkar R.R., et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. N. Engl. J. Med. 2011;364:2187–2198. doi: 10.1056/NEJMoa1103510. - DOI - PubMed
    1. Leon M.B., Smith C.R., Mack M.J., Makkar R.R., Svensson L.G., Kodali S.K., Thourani V.H., Tuzcu E.M., Miller D.C., Herrmann H.C., et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N. Engl. J. Med. 2016;374:1609–1620. doi: 10.1056/NEJMoa1514616. - DOI - PubMed
    1. Latif A., Ahsan M.J., Lateef N., Kapoor V., Mirza M.M., Anwer F., Del Core M., Kanmantha Reddy A. Outcomes of surgical versus transcatheter aortic valve replacement in nonagenarians—A systematic review and meta-analysis. J. Community Hosp. Intern. Med. Perspect. 2021;11:128–134. doi: 10.1080/20009666.2020.1843235. - DOI - PMC - PubMed
    1. Gasior T., Mangner N., Bijoch J., Wojakowski W. Cerebral embolic protection systems for transcatheter aortic valve replacement. J. Interv. Cardiol. 2018;31:891–898. doi: 10.1111/joic.12573. - DOI - PubMed

LinkOut - more resources